Lawrenceville, NJ, United States of America

Ricardo Attar

USPTO Granted Patents = 24 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 7.9

ph-index = 7

Forward Citations = 247(Granted Patents)

Location History:

Spring House, PA (US) (2017 - 2018)
Lawrence Township, PA (US) (2020)
Lawrence Township, NJ (US) (2021)
Lawrenceville, NJ (US) (2002 - 2024)

Company Filing History:

10 out of 3,681

Bristol-myers Squibb Compnay

patents

9 out of 410

Janssen Biotech, Inc.

patents

4 out of 2,076

Janssen Pharmaceutica Nv

patents

4. 1 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

5. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12304939 - EGFR and C-met fibronectin type III domain binding molecules (2025-05-20),

2. 12077592 - GPRC5D chimeric antigen receptors and cells expressing the same (2024-09-03),

3. 12018289 - Vaccines based on mutant CALR and JAK2 and their uses (2024-06-25),

4. 11884722 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2024-01-30),

5. 11685777 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2023-06-27),

6. 10954284 - EGFR and c-Met fibronectin type III domain binding molecules (2021-03-23),

7. 10774130 - Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins (2020-09-15),

8. 10662235 - Cysteine engineered fibronectin type III domain binding molecules (2020-05-26),

9. 10562968 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2020-02-18),

10. 10106620 - Blocking CD38 using anti-CD38 F(ab')2 to protect NK cells (2018-10-23),

11. 10072088 - Anti-BCMA antibodies and uses thereof (2018-09-11),

12. 9902762 - Multivalent fibronectin based scaffold domain proteins (2018-02-27),

13. 9850310 - CD123 binding agents and uses thereof (2017-12-26),

14. 9725497 - EGFR and C-Met fibronectin type III domain binding molecules (2017-08-08),

15. 9695228 - EGFR and c-Met fibronectin type III domain binding molecules (2017-07-04),

Title: Inventor Spotlight: Ricardo Attar

Introduction

Ricardo Attar is a distinguished inventor based in Lawrenceville, NJ, known for his significant contributions to the field of biomedical innovations. With a remarkable portfolio of 23 patents, Attar's work primarily focuses on the development of cutting-edge treatments for cancer.

Latest Patents

Among his notable inventions are two recent patents that highlight his innovative spirit. The first, titled "GPRC5D Chimeric Antigen Receptors and Cells Expressing the Same," offers a breakthrough in targeted cancer therapies by utilizing chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, GPRC5D. This innovation encompasses immunoresponsive cells equipped with such CARs for effective cancer treatment. The second patent, "Vaccines Based on Mutant CALR and JAK2 and Their Uses," presents a novel approach to immunotherapy. It includes vaccines, polypeptides, and polynucleotides based on mutant CALR and JAK2 sequences, along with comprehensive methods to induce immune responses and manage clinical conditions associated with these mutations.

Career Highlights

Ricardo Attar has worked for prestigious companies in the pharmaceutical sector, including Bristol-Myers Squibb Company and Janssen Biotech, Inc. His extensive experience in these organizations has honed his expertise in drug development and innovation, making substantial advancements in therapeutic solutions for patients.

Collaborations

Throughout his career, Attar has collaborated with eminent professionals in the field. Notable coworkers include Marco Gottardis and Francois Gaudet, both of whom share a commitment to advancing cancer treatments and enhancing patient outcomes through innovative research and development.

Conclusion

Ricardo Attar's passion for innovation and his dedication to improving cancer therapies through his patents underscore his role as a trailblazer in the biomedical field. His contributions have the potential to transform therapeutic approaches, providing hope and enhanced treatment options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.